By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – ExonHit Therapeutics today announced it is terminating its agreement to buy RedPath Integrated Pathology, following a decision by Medicare to limit its coverage for RedPath's portfolio of tests only to its pancreatic test.

The decision comes after ExonHit and RedPath were unable to agree on revised terms and conditions following the decision by Medicare contractor Highmark Medicare Services to cover only RedPath's TG-Pancreatic cancer test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: mtDNA analysis give glimpse into decline of Neanderthals in Europe, and more.

The University of Arizona's Raina Maier writes that an understanding of the Earth's microbiome is needed.

The proposed Canadian budget emphasizes partnerships with industry, Nature News reports.

An Australian study of personalized medicine has run into problems as it recruits patients.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.